Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

GLP-1 Receptor Agonists and Kidney Protection

Open access

Abstract

Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomerular filtration rate (GFR). Apart from renin–angiotensin–aldosterone system (RAAS) inhibitors, no other drugs are currently available as therapy for diabetic kidney disease (DKD). Glucagon-like peptide-1 receptor (GLP-1R) agonists are a new class of anti-hyperglycemic drugs which have been demonstrated to prevent the onset of macroalbuminuria and reduce the decline of GFR in diabetic patients. These drugs may exert their beneficial actions on the kidneys through blood glucose- and blood pressure (BP)-lowering effects, reduction of insulin levels and weight loss. Clinical benefits of GLP-1R agonists were acknowledged due to data from large randomized phase III clinical trials conducted to assess their cardiovascular(CV) safety. These drugs improved renal biomarkers in placebo-controlled clinical studies, with effects supposed to be independent of the actions on glycemic control. In this review, we will focus on the actions of GLP-1R agonists on glucose metabolism and kidney physiology, and evaluate direct and indirect mechanisms through which these drugs may confer renal protection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/medicina55060233

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (a) Chronic administration of glucagon-like protein-1 receptor (GLP-1R) agonists has been shown to affect renal hemodynamics through decreasing the estimated glomerular filtration rate (eGFR). (b) The antialbuminuric actions of GLP-1R agonists on kidneys involve effects on multiple mechanisms of diabetic nephropathy (DN).
Figure 1 (a) Chronic administration of glucagon-like protein-1 receptor (GLP-1R) agonists has been shown to affect renal hemodynamics through decreasing the estimated glomerular filtration rate (eGFR). (b) The antialbuminuric actions of GLP-1R agonists on kidneys involve effects on multiple mechanisms of diabetic nephropathy (DN).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 173

Metadata

Authors
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S.
Affiliations
  • Casa Sollievo della Sofferenza (IT)
  • University of Messina (IT)
  • Ospedale Policlinico San Martino (IT)
  • Unit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo (FG), Italy
Venue
Medicina
Publisher
MDPI AG
Published
2019-05-31
Volume
55
Issue
6
Pages
233
ISSN
  • 1010-660X (ISSN-L)
  • 1648-9144
OpenAlex
W2947335986
Cited by
173
References
49
Citations by year
2026: 18 · 2025: 36 · 2024: 37 · 2023: 17 · 2022: 32 · 2021: 17 · 2020: 14 · 2019: 2
FWCI
2.54
Type
journal article
Language
en
Open access
Locations
  • Medicina (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
GLP-1 receptor agonists, renal protection, diabetic nephropathy, type 2 diabetes, chronic kidney disease, albuminuria, glomerular filtration rate decline, renin-angiotensin-aldosterone system, blood pressure reduction, insulin reduction, weight loss, renal biomarkers, cardiovascular safety
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Kidney, Protective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 Receptor Agonists and Kidney Protection. https://app.cochat.ai/papers/10.3390/medicina55060233
The paper
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019). GLP-1 Receptor Agonists and Kidney Protection. Medicina. https://doi.org/10.3390/medicina55060233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.